Search results
Found 228 matches for
Major rise in public support for COVID vaccine – Oxford study
Coronavirus COVID-19 General Research
24 February 2021
More than three quarters of people in the UK now say they are ’very likely’ to have the vaccine – up from 50% among the same group of survey respondents five months ago –according to a two-wave Oxford University survey published today.
Coronavirus vaccination linked to substantial reduction in hospitalisation, real-world data suggests
Coronavirus COVID-19 General Research
22 February 2021
The first study to describe the effects in real-world communities of the Oxford coronavirus vaccine has been reported in a pre-print publication today, showing a clear reduction in the risk of hospitalisation from COVID-19 amongst those who have received the vaccine.
World’s largest clinical trial for COVID-19 treatments expands internationally
Clinical Trials Coronavirus COVID-19 General
18 February 2021
The Randomised Evaluation of COVID-19 Therapy (RECOVERY) Trial, the world’s largest clinical trial for COVID-19 treatments, has now expanded internationally with Indonesia and Nepal among the first countries to join. The first patients have been recruited to RECOVERY International.
Oxford-led technology to help those at high risk from Covid-19
Coronavirus COVID-19 General Research
16 February 2021
More people in England at high risk from Covid-19 will get priority access to vaccines thanks to new technology developed by a University of Oxford-led team of researchers that can identify those who may be most vulnerable to the virus.
World Health Organization lists Oxford coronavirus vaccine for emergency use
Clinical Trials Coronavirus COVID-19 General
15 February 2021
The Oxford / AstraZeneca vaccine has today been granted Emergency Use Listing (EUL) by the World Health Organization (WHO) for active immunisation to prevent COVID-19 in individuals 18 years of age and older, including those over 65.
Oxford University extends COVID-19 vaccine study to children
Clinical Trials Coronavirus COVID-19 General
12 February 2021
The University of Oxford, together with three partner sites in London, Southampton and Bristol, is to launch the first study to assess the safety and immune responses in children and young adults of the ChAdOx1 nCoV-19 coronavirus vaccine.
Tocilizumab reduces deaths in patients hospitalised with COVID-19
Coronavirus COVID-19 General Research
11 February 2021
The Randomised Evaluation of COVID-19 Therapy (RECOVERY) has demonstrated that an anti-inflammatory treatment, tocilizumab, reduces the risk of death when given to hospitalised patients with severe COVID-19. The study also showed that tocilizumab shortens the time until patients are successfully discharged from hospital and reduces the need for a mechanical ventilator.
Drug trial that could improve respiratory recovery from COVID-19 now underway
Clinical Trials Coronavirus COVID-19 General
10 February 2021
A clinical trial has commenced this week to test whether a drug called Almitrine can help people who are seriously ill with COVID-19 to recover from the disease.
Common asthma treatment reduces need for hospitalisation in COVID-19 patients, study suggests
Coronavirus COVID-19 General Research
9 February 2021
Early treatment with a medication commonly used to treat asthma appears to significantly reduce the need for urgent care and hospitalisation in people with COVID-19, researchers at the University of Oxford have found.
NHS COVID-19 contact tracing app averted between 200,000 and 900,000 infections, estimates infectious disease experts
Coronavirus COVID-19 General Research
9 February 2021
A team of medical research and statistical modelling experts at Oxford University and the Alan Turing Institute have conducted a joint analysis to assess the impact of the NHS COVID-19 contact tracing app.
ChAdOx1 nCov-19 provides minimal protection against mild-moderate COVID-19 infection from B.1.351 coronavirus variant in young South African adults
Clinical Trials Coronavirus COVID-19 General
8 February 2021
In an analysis, submitted as a pre-print prior to peer-review publication, a two-dose regimen of the ChAdOx1 nCoV-19 vaccine provides minimal protection against mild-moderate COVID-19 infection from the B.1.351 coronavirus variant first identified in South Africa.
Oxford vaccine effective against major B.1.1.7 ‘Kent’ coronavirus strain circulating in the UK
Clinical Trials Coronavirus COVID-19 General
5 February 2021
A preprint of ongoing work to assess effectiveness of Oxford’s ChAdOx1 coronavirus vaccine shows that the existing vaccine has similar efficacy against the B.1.1.7 ‘Kent’ coronavirus strain currently circulating in the UK to previously circulating variants.
Oxford leads first trial investigating dosing with alternating vaccines
Clinical Trials Coronavirus COVID-19 General
4 February 2021
The University of Oxford is to lead the first trial to explore alternating different COVID-19 vaccines, to explore the potential for flexibility in delivery and look for clues as to how to increase the breadth of protection against new virus strains.
Understanding the first wave of COVID-19 and implications for tackling the ongoing pandemic: evidence from 5.5 million people from Catalonia, Spain
Coronavirus COVID-19 General Research
3 February 2021
Health outcomes during the first wave of COVID-19 in Catalonia, Spain, have been described in detail in a study published by Nature Communications.
Oxford coronavirus vaccine shows sustained protection of 76% during the 3-month interval until the second dose
Clinical Trials Coronavirus COVID-19 General Research
2 February 2021
Researchers at the University of Oxford have today published in Preprints with The Lancet an analysis of further data from the ongoing trials of the vaccine. In this, they reveal that the vaccine efficacy is higher at longer prime-boost intervals, and that a single dose of the vaccine is 76% effective from 22- to up to 90-days post vaccination.
Indonesia’s decision to prioritise COVID-19 vaccination to citizens aged 18-59 years old questionable
Coronavirus COVID-19 General
2 February 2021
European Medicines Agency recommends conditional marketing authorisation to ChAdOx1 coronavirus vaccine
Coronavirus COVID-19
29 January 2021
The European Medicines Agency (EMA) has today recommended the conditional marketing authorisation of the ChAdOx1 nCoV-19 coronavirus vaccine developed by the University of Oxford with its partner AstraZeneca. Distribution will begin across all 27 member states once the decision is ratified by the European Commission.
Oxford University vaccine developer joins day of vaccinations at the Kassam Stadium
Coronavirus COVID-19 General
26 January 2021
Today, Andrew Pollard, Professor of Pediatric Infection and Immunity at the University of Oxford, and chief investigator of the trials of the ChAdOx1 nCoV-19 coronavirus vaccine, volunteered his time to help deliver live-saving Covid vaccinations at the newly opened NHS Vaccine Centre at the Kassam Stadium, Oxford.
PRINCIPLE trial finds antibiotics azithromycin and doxycycline not generally effective treatments for COVID-19
Coronavirus COVID-19 General Research
25 January 2021
In March 2020, the UK-wide Platform Randomised trial of INterventions against COVID-19 In older people (PRINCIPLE) trial was established as a flexible, platform randomised clinical trial to test a range of potential treatments for COVID-19 that might be suitable for use in the community to help people recover more quickly and prevent the need for hospital admission. The trial is one of three national platform trials for COVID-19 treatments, and complements the RECOVERY and REMAP-CAP trials that focus on hospitalised patients.
Early animal studies yield promising results for new potential COVID-19 vaccine
Coronavirus COVID-19 General Research
25 January 2021
Studies carried out in the MRC Human Immunology Unit (MRC HIU) in collaboration with the Pirbright Institute have shown that a new potential vaccine against COVID-19, named RBD-SpyVLP, produces a strong antibody response in mice and pigs, providing vital information for the further development of the vaccine. Although this type of vaccine is not a competitor for the first wave of vaccines, it is hoped that it will be useful as a standalone vaccine or as a booster for individuals primed with a different COVID-19 vaccine.